Stay up-to-date with the Dr Reddys Stock Liveblog, your trusted source for real-time updates and thorough analysis of a ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Dr Reddy's Laboratories share price gained almost 3% in the morning trades on Thursday post Q1 results that were declared ...

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years. Dr. Reddy’s ...

Hyderabad: Dr. Reddy’s Laboratories Ltd has announced an investment of Rs 565.4 crore in its step-down wholly owned ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Leading pharmaceutical major Dr Reddys Laboratories is set to announce its Q1FY26 financial results on. Markets top analysts ...

Investors seeking Dr. Reddy’s Laboratories' final dividend of Rs 8 per share for FY25 must purchase shares by today, July 9, as it is the last day to qualify. The record date is set for July 10, 2025, ...

The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.

Erez Israeli, CEO of Dr Reddys Laboratories, said that the company has no plans to shift manufacturing to the US unless it ...

The company is going to announce results for the quarter ended June 30th, 2025 on July 23, 2025 after the board meeting.